Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

Published Date: 02 Apr 2026

A dose-dense modified Stanford V regimen may improve early complete responses and allow some pediatric patients with low-risk Hodgkin lymphoma to skip radiotherapy.

Read Full News

Latest News

Morning Immunotherapy Does Not Boost Lung Cancer Survival

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung cancer begs to differ.

Skipping Lymph Node Biopsy Gains Ground in Breast Cancer

New data show growing adoption of guidance to skip sentinel lymph node biopsy in older women with early breast cancer, though uptake remains slow and incomplete in the US.

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

Can MRI Curb Chemo Overtreatment in Breast Cancer?

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

New Gene Therapy Nears EU Nod for Bladder Cancer

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

Todays Updates

Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC

In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated with reduced treatment response.

Todays Updates

Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC

In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated with reduced treatment response.

Latest News

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung cancer begs to differ.

New data show growing adoption of guidance to skip sentinel lymph node biopsy in older women with early breast cancer, though uptake remains slow and incomplete in the US.

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

News All Time

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

Older Adults With Advanced Cancer Prioritize Quality of Life

Most older adults with advanced cancer value quality of life over extending survival, but that preference may not translate to clinical care or outcomes.

MRI-Guided TULSA Speeds Recovery vs Robotic Prostatectomy

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

Shorter but More Intense RT: A Better Option for HNSCC?

A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.

Adjuvant Tx May Boost Survival in Bilateral Breast Cancer

A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.

Chemoimmunotherapy Boosts Head and Neck Cancer Response

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Have the Harms of Lung Cancer Screening Been Exaggerated?

Three medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

Despite FDA package insert recommendations, most patients with breast cancer who are prescribed CDK4/6 inhibitors do not receive liver function tests before starting treatment.

Alternative Medicine for Breast Cancer: Study Raises Concern

Patients who receive both standard medical treatment and complementary and alternative therapies have higher mortality — possibly due to reduced use of endocrine therapy and radiation.

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Recommended News For You

Best foot forward—chemo care should include podiatry, say researchers

Study: For predicting breast cancer, AI performs better than traditional risk models.

The need for more Latinx participants in Alzheimer's trials is urgent.

Single-dose radiation before surgery can eradicate breast cancer

Breast cancer: A new target to eliminate dormant cells before they wake

FDA Approves Hemophilia B Second Gene Therapy.

ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

Recommended Articles For You

Ethics of Experimental Oncology: Case Study on Autonomy, Consent & Decision-Making 

Optimizing Platelet Transfusions: Balancing Benefits and Risks in Modern Hematology 

Mastering Modern Oncology: Accreditation, Education, and Research Trends for 2025 

Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Global inequalities found in cancer research funding

2.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

3.

Review looks at potential treatment targets in the tumor microenvironment.

4.

Accurately identified high-grade prostate cancer through urine testing.

5.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.

1.

Ticagrelor Monotherapy vs. Ticagrelor + Aspirin in ACS Post-PCI: ULTIMATE-DAPT Trial

2.

AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency

3.

Hematologic Cytomorphology: From Microscopy to Molecular Diagnostics

4.

Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies

5.

Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A New Era in Managing Cancer-Associated Thrombosis

2.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

3.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

4.

Efficient Management of First line ALK-rearranged NSCLC - Part III

5.

Newer Immunotherapies for Myeloma- A Comprehensive Overview


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot